|Awarded On||February 19, 2020|
|Title||Circulating Tumor DNA- Defined Minimal Residual Disease in Colorectal Cancer|
|Award Mechanism||Individual Investigator Research Awards for Clinical Translation|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Arvind Dasari|
*Pending contract negotiation
Circulating tumor DNA (ctDNA) are tiny fragments of DNA shed by cancer cells that can be detected in the blood of cancer patients. Detection of ctDNA after completion of all curative intent therapies in the absence of any cancer on scans (i.e. minimal residual disease, MRD) is associated with a very high risk of recurrence. Thus, ctDNA is a very good marker for stratifying risk of recurrence and holds great promise in radically changing our approach to taking care of CRC patients. However, since only small amounts ctDNA are present after surgery, more sensitive assays for MRD are needed. Furthermore, whether patients whose ctDNA disappears with chemotherapy have improved survival is unknown...